Development and contextual adaptation of the first national clinical practice guideline for autism spectrum disorder in children and adolescents in Tunisia

IntroductionAutism Spectrum Disorder (ASD) is a neurodevelopmental condition requiring long-term, coordinated, and multidisciplinary care. Although ASD services in Tunisia have improved, coordination across health, education, and social sectors remains limited, affecting equitable access and continuity of care. This study aimed to develop a national, evidence-based clinical practice guideline for the screening, diagnosis, and management of children and adolescents with ASD adapted to the Tunisian healthcare context.Assessment of guideline development and practice implicationsThe guideline was developed by the Tunisian Society of Child and Adolescent Psychiatry and accredited by the National Authority for Evaluation and Accreditation in Health. Using the ADAPTE framework, a multidisciplinary panel adapted international ASD guidelines to the Tunisian context. After systematic searches and AGREE II appraisal, the 2023 Singapore ASD guideline was selected as the main source document. Recommendations were adopted, adapted, or newly developed according to contextual relevance and applicability. An additional literature search was performed to incorporate high-level evidence published between June 2023 and January 2025.Actionable recommendationsThe final guideline includes 96 evidence-based recommendations and 87 good practice points organized into ten chapters, covering the screening, diagnosis, intervention, and follow-up of autism spectrum disorder in children and adolescents across all levels of care in Tunisia. This article summarizes the key practice-oriented recommendations across these chapters.ConclusionThis first Tunisian ASD guideline aims to harmonize practices, improve the quality of care, and strengthen integrated care pathways.

What Is Guanfacine?

Guanfacine is a non-stimulant medication that is FDA-approved to treat ADHD in children and teens. It can also be used off label to treat tic disorders and symptoms of autism.

Guanfacine is not as powerful in reducing ADHD symptoms as stimulant medications, but it’s especially helpful for children who are hyperactive and impulsive — who can’t sit still in class, blurt out answers, interrupt, melt down easily, or have trouble shifting gears. 

“I always describe guanfacine as a behavioral medication,” says Paul Mitrani, MD, PhD, a child and adolescent psychiatrist at the Child Mind Institute. It can help kids who struggle to regulate their impulses and emotions take time to pause before acting.

What is guanfacine?

Guanfacine is a kind of medication called an alpha-2A adrenergic receptor agonist. Alpha-2 agonists — including guanfacine and clonidine, among others — were originally developed to treat adults with hypertension, or high blood pressure. But guanfacine may be best known as a treatment for ADHD.

Guanfacine (under the brand name Intuniv) was officially approved to treat ADHD in children in 2009 but has been used for this purpose since the 1990s.

How does guanfacine work?

The alpha-2A receptors that guanfacine targets are found in various regions of the brain and nervous system, but heavily concentrated in the prefrontal cortex, the part of the brain that helps regulate attention, emotion, impulsivity, and behavior.

Researchers don’t fully understand how guanfacine works, but it is thought to act by enhancing the functioning capabilities of those alpha-2A- receptors in the prefrontal cortex, improving a person’s ability to focus “above the noise” of the environment.

Guanfacine also has a calming effect by acting on alpha-2A receptors in the sympathetic nervous system, reducing sympathetic nerve impulses. This calming effect is especially helpful for hyperactivity and impulsivity. (The sympathetic nervous system also regulates blood pressure, thus the drug’s original use.)

Guanfacine and ADHD

Guanfacine can be used to treat ADHD on its own, but it is commonly used in addition to a stimulant.

The first-line medication treatment for ADHD, for both children and adults, is a stimulant medication like methylphenidate (Ritalin) or amphetamine (Adderall). Guanfacine, however, is a non-stimulant drug — it can target the same symptoms, it just goes about it in a different way.

Still, Dr. Mitrani adds: “We don’t typically start with guanfacine as a medication for ADHD unless the behaviors are more of the problem or there’s concern about starting a stimulant.”

For example, guanfacine may be beneficial for a child who does well academically but has trouble settling down and following rules in class. “I see kids who are really bright, so they don’t have to pay full attention to do well in school but can still struggle with behaviors that are causing a problem,” says Dr. Mitrani. For other kids, “they may benefit from a stimulant for their attention and behaviors, but parents are concerned that a stimulant may result in them not eating, which can impact growth. That’s where I may start with guanfacine.”

For some children, adding guanfacine can also address issues associated with stimulant medications, including sleep problems and the “crash” in mood and behavior that some kids experience at the end of the day, when they’re coming off a stimulant. Guanfacine may make kids drowsy, so it’s usually taken at night, says Dr. Mitrani. That means it can offset side effects of a stimulant by helping kids get tired when it’s time for bed. But some kids take guanfacine in the morning without feeling sleepy during the day, he adds.

What are the side effects of guanfacine?

Sleepiness: A common side effect of guanfacine is sleepiness or fatigue. But if a child is really tired after taking guanfacine, says Dr. Mitrani, it’s probably not a great fit. “Tiredness is the one side effect we are most concerned with because if it makes you tired, it’s not a good medicine for you.”

If a child is taking guanfacine in addition to a stimulant, consider their whole medication schedule when discussing any concerns with their pediatrician. “For example,” says Dr. Mitrani, “if they don’t take their stimulant on the weekend, but they stay on the guanfacine, they may feel more tired on the weekends than they do during the week because the stimulant is helping balance things out.”

Low blood pressure: Guanfacine can also lower blood pressure, which can cause dizziness. “Most kids tolerate any small drop in blood pressure fine because their hearts are young and healthy and they compensate with an increased heart rate,” Dr. Mitrani says. But other possible side effects related to lower blood pressure (hypotension) include constipation, dry mouth, or headaches.

What are the different kinds of guanfacine?

There are two kinds of guanfacine: immediate-release (IR), which lasts for several hours, and extended-release (ER), which lasts all day.

Immediate-release (IR) guanfacine: Guanfacine IR (previously known by the brand name Tenex) is used off label to treat ADHD and other disorders. Guanfacine IR is absorbed faster, peaks earlier, and lasts for less time than the extended-release version. Children typically take more than one dose per day.

Guanfacine ER (Intuniv): Guanfacine ER is FDA-approved to treat ADHD in children ages 6 through 17, either alone or in addition to stimulants. Guanfacine ER is available in a range of doses, typically starting at 1mg, and is taken once per day.

Notes on dosing: The recommended pediatric dose of guanfacine ER is 1–4mg daily for children 6 to 12. Children 13 to 17 are FDA-approved to receive a dose up to 7mg. But some young children tolerate and benefit from doses above 4mg, says Dr. Mitrani. Still, any amount of the drug should be handled with caution. If a decision is made for a child to stop taking guanfacine, the dose should be tapered off over a period of time, usually several weeks. Stopping the medication abruptly, particularly at a higher dose, can cause a spike in blood pressure, Dr. Mitrani explains.

Short- and long-acting forms of guanfacine are not interchangeable in terms of dosing. For example, if your child is taking guanfacine ER 2mg, that doesn’t mean it would be appropriate for them to make a direct switch to guanfacine IR 2mg — these medicines are not equivalent because of the way they are absorbed. If a child switches medications, their dose must be adjusted.

Guanfacine vs clonidine

Guanfacine isn’t the only drug of its class that can be used to help with ADHD symptoms like hyperactivity or impulsivity. Another commonly used alpha-2 agonist is called clonidine (Catapres, Kapvay). Clonidine, FDA-approved to treat ADHD in children 6 to 17, essentially works the same way as guanfacine but tends to be a little more potent. As a result, side effects like sleepiness can be more pronounced, so it’s usually not the first choice, says Dr. Mitrani.

On the positive side, newer versions of clonidine (Onyda XR) are available in liquid form, which makes it possible to control the dose to a finer degree. “With guanfacine, in its long-acting form, you’re working with 1 milligram, 2 milligrams, 3 milligrams, etcetera,” Dr. Mitrani explains. “With the liquid clonidine, you could do 0.15 milligrams or 0.25 milligrams. So, you can optimize the dose, and hopefully, reduce any negative side effects.”

Liquid clonidine, which, like guanfacine ER, lasts 24 hours, is also a good option for kids with sensory issues or an aversion to swallowing pills. Guanfacine ER tablets cannot be crushed or broken because then the medication may be released too quickly. Children must swallow time-release tablets whole.

Guanfacine and tic disorders

Guanfacine has been shown to be effective in treating some children with tic disorders. Researchers aren’t entirely sure why guanfacine can reduce tic severity, and their thinking has shifted in recent years. They theorize that the drug’s effects on the prefrontal cortex may help regulate attention and suppress tics.

Some studies show that the short-acting version of guanfacine, which kids typically take two to three times a day, can help manage tics better, says Dr. Mitrani. “Tics wax and wane; they come and go,” he explains. “They can be triggered by being excited, being tired, or being stressed.” Immediate-release guanfacine may be better-suited to address these fluctuations.

Kids with tic disorders often have other disorders, including ADHD. Studies show that guanfacine is more effective for kids with tics and ADHD than kids with tic disorders alone.

Guanfacine and autism

Guanfacine can also be prescribed off label to help treat autism. It may be effective in these cases because it helps regulate symptoms that are similar to or associated with ADHD, such as hyperactivity, impulsivity, and distractibility. (Researchers estimate that about one-third of children with autism also have ADHD.) Guanfacine is also sometimes used to address irritability, oppositional behavior, or problematic repetitive behaviors.

The post What Is Guanfacine? appeared first on Child Mind Institute.

In-person UCLA-PEERS® program for adolescents with autism spectrum disorder in Italy: study protocol for a pilot and feasibility randomized controlled trial with pragmatic features and exploratory EEG markers of treatment response

BackgroundAdolescents with Autism Spectrum Disorder (ASD) Level 1 frequently experience persistent difficulties in peer relationships and social functioning that become more evident as social demands increase. Group-based social skills trainings represent a key evidence-based intervention for this population, yet its availability in routine clinical services is still limited. The Program for the Education and Enrichment of Relational Skills (PEERS®) is one of the most empirically supported interventions for autistic adolescents. In Italy, telemedicine delivery has shown promising results, but the effectiveness and implementation of the in-person format in real-world services have not yet been evaluated. In addition, predictors of individual response to psychosocial interventions remain largely unknown.MethodsThis study is designed as a two-arm pilot and feasibility randomized controlled trial incorporating pragmatic features, including delivery within a routine tertiary clinical service, comparison with Treatment as Usual (TAU), and allowance for ongoing concomitant clinical, educational, and pharmacological treatments. It will compare the in-person Italian adaptation of UCLA PEERS® with Treatment as Usual (TAU) at IRCCS Fondazione Stella Maris (Pisa, Italy). Thirty-six adolescents aged 11–13 years with ASD (DSM-5-TR) and Full-Scale IQ >85 will be assessed at baseline (T0) and after the 16-week intervention (T1). Randomization will use block allocation with allocation concealment until completion of baseline assessments; outcome assessors and independent ADOS–BOSCC video coders will remain blind to group assignment. The intervention includes sixteen weekly 90-minute group sessions delivered by certified providers, with parallel caregiver sessions and structured teacher contacts to promote generalization. The primary focus of this pilot trial is feasibility, assessed through recruitment, retention, session attendance, and treatment fidelity. Clinical outcomes will be examined exploratorily to provide preliminary estimates of treatment effects. The QSQ-R will serve as the prespecified principal clinical outcome for estimating change in social functioning from baseline to T1. Parent- and adolescent-report versions will be analyzed separately, considering the Social Initiative and Social Reciprocity dimensions as distinct outcomes rather than deriving a composite total score. Key secondary outcomes include social knowledge (TASSK-R), autism-related social responsiveness (SRS-2), social motivation (SSDS), social anxiety (SAS), and observational change in social-communication behaviors (ADOS–BOSCC). Emotional–behavioral functioning (CBCL; YSR) will be explored as additional secondary outcomes. Baseline electroencephalography (EEG) recorded during a gesture–word integration task will be used to derive the N400 congruency effect and to explore whether individual differences in this measure are associated with treatment response. As a pilot and feasibility trial, the study is not powered for definitive efficacy testing and will estimate feasibility, acceptability, fidelity, and preliminary effect sizes to inform future multicenter trials.DiscussionThis study will provide the first evaluation of in-person PEERS® in the Italian clinical context and test the generalizability of previous telemedicine findings in routine care. The integration of clinical and behavioral outcomes may contribute to mechanism-informed, personalized psychosocial interventions for autistic adolescents and guide the design of future confirmatory studies.Trial registration(ClinicalTrials.gov – NCT07207213 – October, 3, 2025).

Child and Adolescent Mental Health Misinformation on TikTok: Cross-Sectional Mixed Methods Study

<strong>Background:</strong> TikTok is an important source of mental health information for children, adolescents, and young adults, but the accuracy of psychoeducational content remains uncertain. Misleading information may be particularly consequential for younger users, who may have limited digital and health literacy. <strong>Objective:</strong> This study aimed to characterize misinformation and disinformation in TikTok content related to child and adolescent mental health, identify mental health topics disproportionately represented in misleading content, examine whether platform-observable video characteristics could discriminate videos containing misinformation, and explore how viewers responded to this content. <strong>Methods:</strong> We conducted a cross-sectional mixed methods secondary analysis of 122 child and adolescent mental health videos identified from a previously collected dataset of 1000 publicly available TikTok videos. Videos were independently coded for content, intent, authenticity, clinical topic, presenter characteristics, and engagement. An L2-penalized logistic regression using only platform-observable characteristics was evaluated using stratified 5-fold cross-validation; 95% CIs for predictive metrics were estimated using 5000 stratified bootstrap resamples of out-of-fold predictions. Disinformation was analyzed descriptively because only 2 cases were identified. An exploratory thematic analysis was conducted on 116 selected viewer comments. <strong>Results:</strong> Misinformation was identified in 21 of 122 (17.2%; 95% CI 11.5%-24.9%) videos, whereas disinformation occurred in 2 of 122 (1.6%; 95% CI 0.5%-5.8%). Misinformation was most frequent among videos addressing autism spectrum disorders (11/27, 40.7%), impulse control disorders (1/3, 33.3%), and mood disorders (4/13, 30.8%). Professional credentials were not disclosed in 63 of 122 (51.6%) videos, and only 9 of 122 (7.4%) referenced an external scientific source. The observable-feature model demonstrated modest discrimination, with an area under the receiver operating characteristic curve of 0.70 (95% CI 0.56-0.82), balanced accuracy of 0.69 (95% CI 0.58-0.79), recall of 0.67 (95% CI 0.48-0.86), and <i>F</i><sub>1</sub>-score of 0.44 (95% CI 0.32-0.56). Qualitative analysis identified 5 recurring patterns in viewer responses: sharing and validation of lived experiences, discussion of diagnosis and misdiagnosis, frustration with mental health care, peer support and encouragement, and exchanges about treatment and medication experiences. <strong>Conclusions:</strong> A substantial minority of the analyzed TikTok videos contained misinformation, with particularly high proportions among some neurodevelopmental and mood-related topics. Platform-observable characteristics provided only modest discrimination of misinformation, underscoring the difficulty of identifying misleading mental health content from surface-level features alone. Viewer comments further showed that TikTok mental health content is embedded within broader processes of self-interpretation, diagnostic discussion, peer validation, and treatment-related exchange. These findings support the need for developmentally appropriate digital health literacy initiatives and accurate, transparently sourced psychoeducational content for young social media users. <strong>Trial Registration:</strong>

Newly Identified Microexons Offer Clues to Autism Spectrum Disorder’s Genetic Roots

Scientists from the University of Toronto, the Sloan Kettering Institute, King’s College London, and the Francis Crick Institute have published data that points to a role for several new microexons in the development of autism spectrum disorder (ASD). According to the findings, published today in Nature, the scientists identified hundreds of new microexons that appear to be involved in ASD and other neurological conditions, and developed a machine learning approach to predict the impact of ASD-associated genetic variants on how these segments are regulated. 

Full details are available in a paper titled “A microexon regulatory code reveals autism-linked genetic variation.” In it, the scientists described how they used a computational tool dubbed MicroExonator to analyze over 100 terabytes of publicly available RNA sequencing data. The tool was developed by Guillermo Parada, PhD, the study’s co-lead author and a postdoctoral fellow in the laboratory of Benjamin Blencowe, PhD,  at King’s and the Crick. Using the tool, he identified more than 1,500 new microexons, of which nearly 300 appeared to be specifically spliced in the brain. Furthermore, many are concentrated in genes associated with critical brain-specific processes, supporting a potential link to neurological health. 

The scientists also explored whether DNA variants found in people with autism might preferentially impact the expanded repertoire of microexons. Specifically they built and applied a machine learning model designed to identify the key regulatory features governing whether a microexon is spliced in or out of messenger RNAs. “What surprised me was that the sequences the model identified as important closely matched those conserved throughout vertebrate evolution,” says Parada.

Next, the scientists applied the model to whole-genome sequence data from thousands of people with autism and neurotypical sibling pairs. Specifically, they analyzed the predicted impact of ASD-associated genetic variants on the microexon regulatory code. “We were able to show that rare genetic variants generally have the largest predicted effects on the splicing of neuronal microexons,” says Blencowe, one of the study’s senior authors and a professor of molecular genetics at University of Toronto. The model further pinpointed a subset of rare variants predicted to alter microexon splicing that are associated with autism.

Additionally, the team found that the variants predicted to affect microexons are predominantly detected among the 85% of autistic individuals that previously lacked a genetic link to autism. This is an important point because “hundreds of genomic variants have been associated with autism, and these deliver a genetic diagnosis in 15 percent of autistic individuals,” says Blencowe, who is also a part-time professor at King’s and the Crick. That means that for 85 percent of people with an ASD diagnosis, the genetic explanation for their condition remains unknown. The findings from this study could provide some answers. 

“In terms of future work, it will be important to understand how disrupted microexons affect interactions between proteins that are important for nervous system development and function,” Blencowe adds. One of the research programs in his lab is also exploring new therapeutic approaches to target microexon dysregulation.

Furthermore, the scientists believe that the machine learning model they developed can be used to characterize other newly discovered genetic variants and their effects in neurological conditions like schizophrenia and epilepsy where microexons are believed to play a role.

 

The post Newly Identified Microexons Offer Clues to Autism Spectrum Disorder’s Genetic Roots appeared first on GEN – Genetic Engineering and Biotechnology News.

X-Chromosome Gene Linked to Increased Autism Diagnosis in Males

Researchers at Baylor College of Medicine, the Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital, and collaborating institutions have identified new genetic candidates that help explain why autism is diagnosed about four times more often in boys than it is in girls. The study, involving tests in induced pluripotent stem cell (iPSC)-derived neurons (iNeurons), revealed that small changes in the gene MECP2 on the X chromosome might help explain part of this difference.

Huda Zoghbi, MD, Distinguished Service Professor at Baylor, director of Duncan NRI, and a Howard Hughes Medical Institute investigator, is senior and corresponding author of the team’s published paper in The American Journal of Human Genetics, titled “A massively parallel reporter assay of MECP2 cis-regulatory elements reveals genetic candidates for male-biased autism.” In their paper, the team concluded, “These findings suggest noncoding MECP2 variants can cause idiopathic, male-biased autism and provide a framework for uncovering regulatory variants in other X chromosome neurodevelopmental genes that may contribute to autism’s missing heritability.”

“Autism is a common, heritable neurodevelopmental trait that affects how a person communicates, interacts with others, and experiences the world, and is characterized by altered social interactions and restricted, repetitive behaviors or interests,” Zoghbi explained. “It is diagnosed about four times more in male individuals than in female individuals, suggesting sex-specific factors may increase male vulnerability,” the researchers added in their paper.

In the current study, the researchers drew from their long experience with gene MECP2, which is on the X chromosome and has been associated with neurodevelopmental conditions, including autism. “We tested the idea that the predominance of autism in males could be explained in part by mild mutations in an X chromosome gene’s regulatory regions,” commented Rebecca Meyer-Schuman, PhD, a postdoctoral associate in the Zoghbi lab. “Females might be protected from such a mild mutation because of their second X chromosome, but males, who have only one copy, would be more vulnerable. The regulatory regions are like dials that control whether a gene will be expressed and by how much. And what better place to start looking at these regulatory regions than the gene MECP2, where brain health depends on how much of the gene is expressed, and where mutations can cause neurodevelopmental disorders that include autism.”

Previous murine studies by Zoghbi lab and others have taught researchers that MECP2 produces a Goldilocks protein, meaning that it must maintain a “just right” concentration or activity level for a healthy brain. Having too little—about 50% or less of the normal levels—leads to Rett syndrome, and having twice the normal levels causes a different neurodevelopmental condition called MECP2 duplication syndrome. “Both loss-of-function and gain-of-function variants lead to severe neurodevelopmental conditions—Rett syndrome (MIM: 312750) and MECP2 duplication syndrome (MDS; MIM: 300260[intellectual developmental disorder, X-linked, syndromic, Lubs type (MRXSL)]), respectively,” the authors commented. “Because MECP2 is on the X chromosome, hemizygous male individuals have a more severe phenotype than heterozygous female carriers with the same variant.”

Meyer-Schuman also noted, “Previous studies in mice also showed us that milder changes in MECP2 levels, for instance reducing the expression by 30% or increasing it by 50%, do not cause the more severe features of Rett syndrome or MECP2 duplication syndrome like seizures or motor problems, but lead to autism-like behaviors.”

For their current study the team used a massively parallel reporter assay (MPRA) to screen the regulatory regions of the MECP2 gene in induced pluripotent stem-cell (iPC)-derived neurons. “This allowed us to identify and manipulate the regulatory regions and determine what kinds of changes would alter their function,” Meyer-Schuman said. The researchers also screened MECP2 regulatory regions in autistic individuals and tested the genetic variants they identified using the MPRA assays.

“We identified two regulatory regions where male autistic individuals inherited a variant from their unaffected mother that altered regulatory activity,” Meyer-Schuman said. “One of these variants reduced MECP2 expression by approximately 30% in human neurons, a magnitude that produces social deficits, hyperactivity and anxiety-like characteristics in mice. As predicted by the mouse model, this individual was diagnosed with autism and ADHD but had none of the defining characteristics of Rett syndrome.”

In their paper, the authors commented that their work supports a broader hypothesis that altered dosage or expression of sex chromosome genes are a major source of the male bias observed in autism. Zoghbi added, “These findings, a result of integrating human and animal studies, suggest that MECP2 regulatory variants can contribute to male-biased autism and reveal just the tip of the iceberg, providing a framework for uncovering regulatory variants in other X chromosome neurodevelopmental genes that may contribute to autism’s missing heritability.”

The post X-Chromosome Gene Linked to Increased Autism Diagnosis in Males appeared first on GEN – Genetic Engineering and Biotechnology News.

Efficacy of stem cell-derived extracellular vesicles in animal models of autism spectrum disorder: a systematic review and meta-analysis

BackgroundAutism spectrum disorder (ASD) is a complicated neurodevelopmental condition that currently lacks a targeted therapy. Although stem cell-derived extracellular vesicles (EVs) represent a potential therapeutic approach for neurological disorders, their efficacy in ASD remains unclear. The objective of this study was to investigate the efficacy of stem cell-derived EVs on autistic-like behaviors in animal models of ASD and to explore the underlying mechanisms.MethodsRelevant studies published up to April 20, 2026 were searched across five databases. Data were pooled using Review Manager 5.4. Outcome measures included behavioral tests and inflammatory cytokine levels.ResultsOut of 1,165 initially retrieved articles, five animal studies met the inclusion criteria. Pooled analyses demonstrated that EV treatment improved autistic-like behaviors in the self-grooming test, three-chamber social interaction test, and marble burying test, and decreased levels of proinflammatory cytokines IL-6 and IL-1β (all P < 0.05). No notable enhancements were observed for the open field test, Morris Water Maze, TNF-α or IL-10 (all P > 0.05).ConclusionStem cell-derived EV therapy may improve repetitive behaviors and social deficits in ASD animal models, with observed associations with reduced IL-6 and IL-1β levels. These preclinical findings suggest promising translational potential of EV-based therapy for ASD.Systematic Review Registrationhttps://osf.io/c78xm, identifier 10.17605/OSF.IO/C78XM.